 |
Abernathy Review |
 |
July, 2008
Work-up and management of differentiated
thyroid cancer and indications/technique for parathyroidectomy.
Dr. Raeburn's "suggestions to the residents"...
Although I’m sure that you all will read all the articles in detail, I recommend that you be sure to read the first 10 pages of the “ATA guideline” paper, the “HPTH-NIH” paper, the “extent of surgery” paper and the “HPTH-neuromotor” paper.
1. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-141.
2. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007;31:895-904.
3. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-141.
4. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375-384.
5. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg 2004;28:1287-1292.
6. Medical observation compared to parathyroidectomy for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007;92:595-603.
7. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism, are they too limited? Ann Surg 2004;239:528-535.
8. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353-5361.